SCHEMBL2367752

SCHEMBL2367752

COc1ccc(C(OCc2cc(CO)cc(-c3ccc4c5cccc6cccc(c7cccc3c74)c65)c2)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.34
PPARA Q07869 3/20 0.34
GPR84 Q9NQS5 1/20 0.33
PPARD Q03181 3/20 0.33
ACACA Q13085 1/20 0.33
BACE1 P56817 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
MAPT P10636 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
C5AR1 P21730 1/20 0.32
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
SLC6A1 P30531 2/20 0.31
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
SLC6A11 P48066 1/20 0.31
ACP1 P24666 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367340 0.93 BACE1 (0.33) PPARGPPARAGPR84PPARDACACA
SCHEMBL2367722 0.89 PPARG (0.43) PPARGPPARAGPR84PPARDACACA
SCHEMBL2368004 0.89 PPARG (0.39) PPARGPPARAGPR84PPARDACACA
SCHEMBL2367563 0.80 BACE1 (0.42) PPARGPPARDBACE1MAPTSLC6A1
SCHEMBL12539335 0.77 RAB9A (0.43) SLC6A1SLC6A11
SCHEMBL13365235 0.77 CYP1A2 (0.36) PPARGPPARAPPARDMAPTMAPK1
SCHEMBL16618219 0.76 CYP1A2 (0.38) BACE1CYP2C19SLC6A1SLC6A11
SCHEMBL19463046 0.76 KIF11 (0.43) SLC6A1SLC6A11
SCHEMBL19689391 0.76 KIF11 (0.38) SLC6A1SLC6A11
SCHEMBL16618237 0.75 MAOB (0.47) PPARDPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366785-B1 OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT, AND USE OF THE LABELING AGENT JAPAN SCIENCE & TECH AGENCY (JP) 2013-01-16 EP disclosed
US-8354515-B2 Oligonucleotide derivative, labeling agent and use for labeling agent JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2013-01-15 US disclosed
US-20120126175-A1 OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT AND USE FOR LABELING AGENT JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2012-05-24 US disclosed
EP-2366785-A1 OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT, AND USE OF THE LABELING AGENT Japan Science And Technology Agency (JP) 2011-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120126175-A1 OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT AND USE FOR LABELING AGENT UPF1, SPIN4, SRRT PPARG 1343/4885PPARA 1658/4885GPR84 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.